Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

Journal:

The Lancet

Published:

2026-02-21

DOI:

10.1016/s0140-6736(25)02276-7

Affiliations:

5

Authors:

8

Go to article

Institutions	Authors	Share
Boston Pharmaceuticals, United States of America (USA)	5.000000	0.63
Liver Institute Northwest, United States of America (USA)	1.000000	0.13
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.13
Houston Methodist Hospital, United States of America (USA)	0.500000	0.06
Houston Methodist Research Institute, United States of America (USA)	0.500000	0.06

Interested in Clinical Sciences?